ACEA Biosciences

ACEA’s cell analysis instruments have been widely adopted globally (>2,500 instruments placed), supporting over ~1,800 peer-reviewed publications. Their platforms are established in preclinical drug discovery/development and basic/clinical research. Clinical results or outcomes from proprietary drug candidates were not detailed in public sources.

For the pharmaceutical pipeline before acquisition—compounds such as AC010 and AC058 were described as “leading clinical compounds” with potential value in large markets with unmet need,[5] but no published trial results or regulatory milestones are available.

The company was acquired by Agilent Technologies in late 2018 for $250 million cash.